Ectopic pregnancy case study
The case
Patient: A 28‑year‑old nulliparous woman presents to the emergency department with acute lower abdominal pain.
Presenting complaint: Sudden onset, crampy lower abdominal pain for 10 hours, radiating to the back, associated with mild dizziness. No vomiting.
History of present illness:
- Pain began 10 hours ago while she was at work; it was initially mild and localized to the suprapubic region, then became progressively severe and diffuse.
- She reports spotting of brownish vaginal discharge for the past 2 days; the flow is scant and not associated with clots.
- She denies fever, chills, dysuria, or bowel changes.
Past obstetric‑gynecologic history:
- Menarche at 13 years, regular 28‑day cycles, lasting 5 days, with moderate flow.
- Last menstrual period (LMP) was 7 weeks ago.
- No prior pregnancies.
- No history of sexually transmitted infections.
Past medical/surgical history:
- Unremarkable. No known chronic illnesses.
Social history:
- Works as a marketing executive.
- Lives with a partner; sexually active, uses condoms inconsistently.
- Non‑smoker, occasional alcohol.
Family history:
- Mother had a tubal ligation; father healthy.
Examination:
| Parameter | Finding |
|---|---|
| General | Alert, mildly pale, appears uncomfortable, diaphoretic |
| Vital signs | BP 100/62 mm Hg, HR 112 bpm, RR 18 /min, Temp 37.2 °C, SpO₂ 98 % on room air |
| Abdomen | Soft, generalized tenderness, maximal in the right iliac fossa; guarding present, no rebound |
| Pelvic exam (speculum) | Cervical motion tenderness, scant brown discharge, no active bleeding |
| Bimanual exam | Uterus normal size, non‑tender; right adnexal fullness with tenderness, left adnexa normal |
| Cardiac & respiratory | Normal |
Initial investigations:
| Test | Result |
|---|---|
| Serum β‑hCG (quantitative) | 3 200 IU/L |
| Hemoglobin (Hb) | 11.2 g/dL |
| Hematocrit (Hct) | 34 % |
| White blood cell count (WBC) | 9.8 × 10⁹/L |
| Platelets | 250 × 10⁹/L |
| Serum progesterone | 12 ng/mL |
| Transvaginal ultrasound (TVUS) | • Empty uterine cavity, no gestational sac <br>• Right adnexal mass 2.5 cm, heterogeneous, “tubal ring” sign <br>• Small amount of free fluid in the pouch of Douglas |
| Blood type & Rh | O‑positive |
| Urine dipstick | Negative for protein, glucose, leukocytes |
The patient is placed on IV access, given 1 L normal saline bolus, and a type‑and‑screen is ordered.
Questions
- What is the most likely diagnosis?
- Which clinical and investigational findings most strongly support this diagnosis?
- Outline the next steps in the diagnostic work‑up, including any additional investigations that may be required.
- Discuss the management options for this patient, indicating the preferred treatment according to current guidelines.
- List the possible short‑ and long‑term complications of the condition and how they should be monitored.
Answers
1. What is the most likely diagnosis?
Ectopic pregnancy, most probably a tubal (ampullary) implantation.
- The combination of a positive quantitative β‑hCG (3 200 IU/L) that is above the discriminatory zone for transvaginal ultrasound (≈1 500 IU/L), an empty uterine cavity, an adnexal mass with the classic “tubal ring” appearance, and mild hemoperitoneum (free fluid) is diagnostic.
- The patient’s LMP (≈7 weeks) and the presence of vaginal spotting further fit the typical presentation.
2. Which clinical and investigational findings most strongly support this diagnosis?
| Finding | Why it points to ectopic pregnancy |
|---|---|
| Positive β‑hCG > discriminatory zone (3 200 IU/L) | At β‑hCG levels >1 500 IU/L a normal intra‑uterine gestational sac should be visible on TVUS; its absence is suspicious. |
| Empty uterine cavity on TVUS | Rules out an intra‑uterine pregnancy at this β‑hCG level. |
| Adnexal “tubal ring” sign (2.5 cm heterogeneous mass) | Highly specific (≈95 % specificity) for tubal ectopic gestation. |
| Free fluid in pouch of Douglas | Suggests rupture or leaking of blood from a tubal pregnancy. |
| Cervical motion tenderness | Classic sign of pelvic irritation from blood or inflammatory fluid. |
| History of irregular condom use | Increases risk of tubal implantation. |
| Mild hypotension & tachycardia | Early signs of intravascular volume depletion due to intra‑abdominal bleeding. |
3. Outline the next steps in the diagnostic work‑up
Repeat quantitative β‑hCG in 48 hours
- A rise of < 66 % (or a plateau) suggests ectopic pregnancy; a rise > 66 % would be expected in a viable intra‑uterine pregnancy.
Serial transvaginal ultrasound (if the initial scan is equivocal)
- Repeat in 24–48 h to assess for evolution of the adnexal mass or appearance of a gestational sac.
Complete blood count and type‑and‑screen (already done)
- To monitor for ongoing blood loss and to prepare for possible transfusion.
Serum progesterone (already obtained)
- Low levels (< 5 ng/mL) favor non‑viable pregnancy; however, it is not diagnostic alone.
Consider laparoscopy if the patient becomes hemodynamically unstable, if β‑hCG rises rapidly (> 1 000 IU/L in 48 h), or if ultrasound shows a clear ruptured tube.
Guideline reference: ACOG Practice Bulletin No. 225 (2023) recommends confirming ectopic pregnancy with a combination of quantitative β‑hCG and TVUS, and using serial β‑hCG and repeat imaging when the diagnosis is uncertain.
4. Discuss the management options and preferred treatment
Management depends on hemodynamic stability, β‑hCG level, size of ectopic mass, and desire for future fertility.
| Scenario | Preferred treatment |
|---|---|
| Hemodynamically stable, β‑hCG < 5 000 IU/L, mass ≤ 3.5 cm, no fetal cardiac activity | Medical management with methotrexate (MTX). |
| Hemodynamically unstable, signs of rupture, large free fluid, or β‑hCG > 5 000 IU/L | Surgical management – laparoscopic salpingostomy or salpingectomy. |
| Contraindications to MTX (e.g., liver disease, immunodeficiency, breastfeeding) | Surgical approach. |
| Patient wishes immediate resolution or has a large mass (> 3.5 cm) or fetal cardiac activity | Surgery. |
Why medical management is preferred for this patient:
- She is currently stable (BP 100/62 mm Hg, HR 112 bpm, responsive to fluid bolus).
- β‑hCG is 3 200 IU/L (below 5 000 IU/L).
- Adnexal mass is 2.5 cm, no cardiac activity seen.
- No absolute contraindications to MTX (normal liver function, not breastfeeding).
Methotrexate regimen (per ACOG 2023):
- Single‑dose protocol: MTX 50 mg/m² intramuscularly on day 0.
- Follow‑up β‑hCG: Day 4 and Day 7; a ≥ 15 % decline between days 4 and 7 confirms response.
- If inadequate decline: Consider second dose or switch to multi‑dose protocol (MTX 1 mg/kg on days 1, 3, 5, 7 with leucovorin rescue).
Pre‑treatment counseling: Discuss potential side‑effects (stomatitis, transaminitis, bone‑marrow suppression), need for reliable contraception for at least 3 months, and importance of follow‑up labs.
If surgical intervention becomes necessary:
- Laparoscopic salpingostomy (incision of the tube to remove the ectopic tissue) preserves fertility and is preferred when the contralateral tube is healthy.
- Laparoscopic salpingectomy (removal of the affected tube) is chosen if the tube is severely damaged or if the patient does not desire future fertility.
5. Possible complications and monitoring
Short‑term complications
- Rupture with hemoperitoneum – can lead to hypovolemic shock; monitor vitals, serial hemoglobin, and repeat US if pain worsens.
- Methotrexate toxicity – hepatic dysfunction (ALT/AST rise), bone‑marrow suppression (neutropenia, thrombocytopenia); check CBC and LFTs on day 4 and day 7.
- Persistent ectopic tissue – may require repeat MTX dose or surgical removal; monitor β‑hCG until < 5 IU/L.
Long‑term complications
- Tubal factor infertility – scarring may reduce fertility; counsel on early fertility assessment if conception does not occur after 12 months.
- Recurrent ectopic pregnancy – risk ~10 %; advise early transvaginal scan in subsequent pregnancies.
- Adhesions – may cause chronic pelvic pain; consider laparoscopy if pain persists.
Monitoring plan
- β‑hCG: Day 0 (baseline), Day 4, Day 7, then weekly until non‑detectable.
- CBC & LFTs: Baseline, Day 4, Day 7 (if MTX given).
- Ultrasound: Repeat TVUS if β‑hCG does not fall appropriately or if clinical status changes.
- Follow‑up visit: 2 weeks after β‑hCG is undetectable to discuss future conception planning and contraceptive options.
Key learning points
- Ectopic pregnancy should be suspected in any woman of reproductive age with abdominal pain, vaginal bleeding, and a positive pregnancy test.
- The discriminatory β‑hCG zone for TVUS (≈1 500 IU/L) is a critical threshold; an empty uterus above this level is highly suspicious.
- The “tubal ring” sign on transvaginal ultrasound is a specific sonographic marker for tubal ectopic gestation.
- Hemodynamic stability dictates the choice between medical (MTX) and surgical management.
- Methotrexate is safe and effective for stable patients with β‑hCG < 5 000 IU/L, mass ≤ 3.5 cm, and no fetal cardiac activity.
- Close follow‑up with serial β‑hCG and monitoring for MTX toxicity is essential to ensure treatment success.
- Early recognition and treatment prevent life‑threatening rupture and preserve future fertility.
Practice MCQs
1. A 30‑year‑old woman presents with a positive pregnancy test, β‑hCG 2 800 IU/L, and a transvaginal scan showing an empty uterus and a 2 cm right adnexal mass. She is hemodynamically stable. Which is the most appropriate next step?
A. Immediate laparoscopic salpingectomy
B. Single‑dose methotrexate therapy
C. Observation only, repeat β‑hCG in 1 week
D. Intravenous antibiotics
Answer: B — The patient meets criteria for medical management (stable, β‑hCG < 5 000 IU/L, mass ≤ 3.5 cm, no cardiac activity).
2. Which of the following ultrasound findings is most specific for a tubal ectopic pregnancy?
A. Intra‑uterine gestational sac with yolk sac
B. “Ring of fire” on Doppler around a corpus luteum cyst
C. “Tubal ring” sign – a hyperechoic ring surrounding an adnexal mass
D. Free fluid without any adnexal mass
Answer: C — The “tubal ring” sign has high specificity for tubal ectopic implantation.
3. According to the 2023 ACOG guidelines, the minimum β‑hCG level at which a gestational sac should be visible on transvaginal ultrasound is:
A. 500 IU/L
B. 1 000 IU/L
C. 1 500 IU/L
D. 2 000 IU/L
Answer: C — The discriminatory zone for a gestational sac on TVUS is ≈1 500 IU/L.
Get a new patient case, answer the examiner's questions by voice or text, and get marked — free.
Try a case on MEDOSTThe patient is invented for teaching. AI-assisted study material for exam revision. Always confirm with standard textbooks and current guidelines; not medical advice.